{"nctId":"NCT03409744","briefTitle":"Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","startDateStruct":{"date":"2018-03-13","type":"ACTUAL"},"conditions":["Homozygous Familial Hypercholesterolemia"],"count":116,"armGroups":[{"label":"evinacumab","type":"EXPERIMENTAL","interventionNames":["Drug: evinacumab"]}],"interventions":[{"name":"evinacumab","otherNames":["REGN1500","EVKEEZAÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Completion of the parent study in which they participated\n2. Able to understand and complete study-related questionnaires\n\nKey Exclusion Criteria:\n\n1. Significant protocol deviation in the parent study based on the investigator's judgment, such as non-compliance by the patient\n2. Concomitant medications that have not been stable prior to the baseline visit\n3. Adverse event leading to permanent discontinuation from parent study\n4. Any new condition or worsening of an existing condition, which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study\n5. Member of the clinical site study team and/or his/her immediate family\n6. Pregnant or breastfeeding women\n7. Women of childbearing potential who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 24 weeks after the last dose of study drug\n8. Men who are sexually active with women of childbearing potential and are unwilling to use the following forms of medically acceptable birth control during the study drug treatment period and for 24 weeks after the last injection of study drug: vasectomy with medical assessment of surgical success OR consistent use of a condom.\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.45","spread":"35.504"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.64","spread":"37.606"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.88","spread":"36.037"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.17","spread":"31.571"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.00","spread":"52.859"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.10","spread":"65.888"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in LDL-C Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-142.1","spread":"114.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-132.0","spread":"124.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-132.8","spread":"133.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-135.1","spread":"121.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-131.4","spread":"129.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-132.5","spread":"132.03"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein B (Apo B) Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.74","spread":"25.338"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.98","spread":"27.574"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.85","spread":"29.998"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.60","spread":"27.292"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.54","spread":"39.969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.73","spread":"51.722"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Apo B Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.0","spread":"59.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.5","spread":"61.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.4","spread":"69.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.9","spread":"61.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.5","spread":"66.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.7","spread":"76.05"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.47","spread":"28.369"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.14","spread":"29.117"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.15","spread":"33.566"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.69","spread":"28.534"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.88","spread":"46.588"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.85","spread":"58.374"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Non-HDL-C Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-153.7","spread":"115.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-143.9","spread":"125.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-144.1","spread":"136.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-147.3","spread":"122.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-144.5","spread":"131.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-142.9","spread":"136.65"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol (TC) Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.04","spread":"20.722"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.17","spread":"24.224"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.78","spread":"27.838"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.58","spread":"25.700"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.33","spread":"38.163"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.92","spread":"47.469"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in TC Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-167.3","spread":"115.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-157.4","spread":"125.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-158.2","spread":"136.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-160.7","spread":"123.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-157.2","spread":"132.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-153.8","spread":"138.26"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides (TGs) Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.97","spread":"26.024"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.93","spread":"24.582"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.25","spread":"37.443"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.50","spread":"25.826"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.28","spread":"24.136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.06","spread":"36.945"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in TGs Over Time","description":"The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.4","spread":"89.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-68.1","spread":"97.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.7","spread":"97.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-68.8","spread":"91.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-75.2","spread":"107.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.7","spread":"110.95"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":116},"commonTop":["Nasopharyngitis","COVID-19","Headache","Influenza like illness","Arthralgia"]}}}